ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer
A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC) compared with historical controls, according to new research from Âé¶¹Ó³» MD Anderson Cancer Center.
Results from the Phase II single arm multicenter trial, presented today at the 2025 American Society of Clinical...

ASCO: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer
Most Americans unaware of cancer risks associated with drinking alcohol
Alcohol is a leading preventable cause of cancer, but public awareness of the connection remains strikingly low in the U.S., with just 40%...
New biomarker may guide best use of KRAS inhibitors in lung cancer
Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib
This biomarker may help physicians determine those most likely to benefit from sotorasib and those who may need alternative or combination?therapies
TTF-1 is a readily available biomarker commonly used for lung cancer diagnostics
Researchers from Âé¶¹Ó³»...

ASCO: MD Anderson¡¯s Christopher Flowers honored for teaching and mentorship
Christopher Flowers, M.D., division head of Cancer Medicine and chair of Lymphoma/Myeloma at Âé¶¹Ó³» MD Anderson Cancer Center...
CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment
Âé¶¹Ó³» MD Anderson Cancer Center today was awarded $21.4 million from the Cancer Prevention and Research Institute of Texas...
UT MD Anderson and Texas Children¡¯s Hospital announce $150 million gift from Kinder Foundation to launch Kinder Children¡¯s Cancer Center
Âé¶¹Ó³» MD?Anderson Cancer Center and Texas Children¡¯s Hospital today announced a $150 million gift from Kinder Foundation...